Cargando…
Radium-223 Treatment in mCRPC Patient with Polycythemia Vera
There have been several studies on the clinical outcomes of Radium-223 treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) who may have an increased risk of hematologic comorbidities. To the best of our knowledge, this is the first study to explore the potential bone m...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522512/ https://www.ncbi.nlm.nih.gov/pubmed/34660164 http://dx.doi.org/10.4274/mirt.galenos.2020.58661 |